Mylan, Ranbaxy Push 3rd Circ. To Nix Provigil Class

Mylan and Ranbaxy said Thursday that purchasers bringing pay-for-delay claims over the narcolepsy drug Provigil have failed to give the Third Circuit any good reason to uphold a class certification order,...

Already a subscriber? Click here to view full article